Clinical Edge Journal Scan

Saxagliptin add-on to oral antihyperglycemic agents safe and effective in drug-naive T2D patients


Key clinical point: Combination of saxagliptin with metformin, acarbose, or gliclazide modified release was safe and effective as an initial treatment option in patients with newly diagnosed type 2 diabetes (T2D) and poor glycemic control.

Major finding: At 24 weeks, the mean changes in glycated hemoglobin (A1c) levels were 2.9% (95% CI 3.1% to 2.8%), 2.6% (95% CI 2.8% to 2.5%), and 2.8% (95% CI 2.9% to 2.6%) in saxagliptin+metformin (Saxa+Met), saxagliptin+acarbose (Saxa+Aca), and saxagliptin+gliclazide (Saxa+Gli) groups, respectively. Overall, 84.9%, 74.7%, and 80.3% of participants achieved an A1c < 7.0% in Saxa+Met, Saxa+Aca, and Saxa+Gli groups, respectively ( P = .05), with the rates of hypoglycemia being low across all groups.

Study details: Findings are from a 24-week, randomized clinical trial including 648 treatment-naive patients with T2D and high A1c level who were randomly assigned to receive Saxa+Met (n = 216), Saxa+Aca (n = 216), or Saxa+Gli (n = 216).

Disclosures: This study was funded by AstraZeneca Pharmaceutical Company. The authors declared no conflicts of interest.

Source: Chen X et al. Saxagliptin combined with additional oral antihyperglycemic agents in drug-naive diabetic patients with high glycosylated hemoglobin: A 24-week, multicenter, randomized, open-label, active parallel-controlled group clinical trial in China (SUCCESS). Diabetes Obes Metab. 2022 (Sep 13). Doi: 10.1111/dom.14873

Recommended Reading

Yoga and other mind-body work good for diabetes control
Type 2 Diabetes ICYMI
Tirzepatide vs. insulin glargine improves renal outcomes in T2D
Type 2 Diabetes ICYMI
Antidiabetic drugs influence fracture risk in T2D
Type 2 Diabetes ICYMI
T2D: Increased risk for ventricular arrhythmia or sudden cardiac death with sulfonylurea vs metformin
Type 2 Diabetes ICYMI
T2D: Bexagliflozin add-on to metformin shows antidiabetic potency equivalent to glimepiride
Type 2 Diabetes ICYMI